window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

multiple sclerosis

  • Central Nervous System,Chronic diseases,Drug Delivery & Formulation,European biotech,Pharmaceuticals and therapeutics

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    October 3, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Market Access & Commercialization,Oncology,Patient Centricity,Regulatory Affairs,Research & Development

    Neuraxpharm expands global reach with launch of Australian affiliate

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on [...]

    July 22, 2025
  • Clinical Development,Drug Development,Precision medicine,Rare Diseases,Technology and platforms

    Rewind Therapeutics strengthens Scientific Advisory Board with leading neurology experts as it advances remyelination therapy

    Appointments enhance clinical expertise as GPR17 modulator progresses toward trials [...]

    July 2, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top